Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Biotechnology

Healthcare
$945.53 -0.90%

-$5.45 today

Market cap
$97.80B
Beta
0.24
P/E (TTM)
14.2
EPS (TTM)
$42.53
Dividend yield
0.60%
52W Low $506.38High $821.11

Volume 0.70M

Average 0.91M

REGN EBITDA Margin

EBITDA as a percentage of revenue.

Regeneron Pharmaceuticals, Inc.NASDAQ: REGN

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 38.7%

EBITDA Margin was 38.7% in Q2 FY2026, down 6.3 pp from a year earlier. On a trailing-twelve-month basis it was 37.0%, down 1.1 pp year over year. Over 3 fiscal years it narrowed by 2.6 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 19 analysts of 47.6% for the fiscal year ending Dec 2026, up from 40.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
38.7%+11.9 pp QoQ
Last fiscal yearDec 2025
40.6%+3.1 pp YoY
LTMJun 2026
37.0%-1.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-6.3 pp-5.9 pp+0.5 pp
1 year+3.1 pp+7.0 pp+3.9 pp
3 years-2.6 pp+6.5 pp+9.2 pp
5 years+8.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
40.6%
Year-over-year change
+3.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How REGN compares with its peers on the latest reported figures

  • REGN's LTM Jun 2026 EBITDA Margin of 37.0% is the 3rd highest of the 9 companies compared; the peer median is 24.6%.
  • Its year-over-year change of -1.1 pp is the 3rd highest of 8, against a peer median of -14.2 pp.
  • Over three fiscal years its change of -2.6 pp compares with a peer median of -2.5 pp.
REGN Competitors Peer median
EBITDA Margin for REGN and competitors
Company Period LTM level YoY 3-year change
AMGNAmgen Inc.LTM Jun 202646.2% +0.7 pp-0.2 pp
NVSNovartis AGLTM Jun 202640.0% -1.1 pp+8.2 pp
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202637.0% -1.1 pp-2.6 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
GMABGenmab A/SLTM Jun 202629.5% —-14.7 pp
BIIBBiogen Inc.LTM Jun 202619.7% -14.2 pp-4.7 pp
GILDGilead Sciences, Inc.LTM Jun 20264.4% -33.6 pp+13.7 pp
OCULOcular Therapeutix, Inc.LTM Mar 2026-527.0% -231.3 pp-361.8 pp
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-3415.1% -3156.5 pp-497.7 pp
Peer median (excluding REGN) 24.6%-14.2 pp-2.5 pp

Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue16.07B12.17B13.12B14.2B14.34B
Cost of Revenue2.72B1.71B2.24B1.97B2.1B
Gross Profit13.35B10.47B10.87B12.23B12.24B
Gross Margin83.1%86.0%82.9%86.1%85.4%
Research & Development2.62B3.06B3.99B5.23B5.85B
Selling, General & Admin1.82B2.12B2.54B2.95B2.7B
Operating Expenses4.4B5.08B6.52B8.24B8.66B
Depreciation & Amortization286.2M341.4M421M482.9M543.7M
EBITDA9.67B5.26B4.69B5.32B5.82B
EBITDA Margin60.2%43.2%35.8%37.4%40.6%
Operating Income8.95B5.39B4.35B3.99B3.58B
Operating Margin55.7%44.2%33.2%28.1%24.9%
Interest Income0160.1M495.9M711.4M716.8M
Interest Expense57.3M59.4M73M55.2M43.8M
Other Income / Expenses379M(526.8M)(149.3M)789.2M1.65B
Income Before Tax9.33B4.86B4.2B4.78B5.23B
Pre-Tax Margin58.0%39.9%32.0%33.7%36.5%
Income Tax Expense1.25B520.4M245.7M367.3M725.8M
Net Income8.08B4.34B3.95B4.41B4.5B
Net Margin50.2%35.6%30.1%31.1%31.4%
EPS (Basic)76.4040.5137.0540.9043.07
EPS (Diluted)71.9738.2234.7738.3441.48
Weighted Avg Shares105.7M107.1M106.7M107.9M104.6M
Weighted Avg Shares (Diluted)112.2M113.5M113.7M115.1M108.6M

Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Intrinsic Alpha fair value

Locked

Current Price

$945.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.